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ABSTRACT Single-dose primaquine (PQ) clears mature gametocytes and reduces
the transmission of Plasmodium falciparum after artemisinin combination therapy.
Genetic variation in CYP2D6, the gene producing the drug-metabolizing enzyme cy-
tochrome P450 2D6 (CYP2D6), inﬂuences plasma concentrations of PQ and its me-
tabolites and is associated with PQ treatment failure in Plasmodium vivax malaria.
Using blood and saliva samples of varying quantity and quality from 8 clinical trials
across Africa (n 1,076), we were able to genotype CYP2D6 for 774 samples (72%).
We determined whether genetic variation in CYP2D6 has implications for PQ efﬁcacy
in individuals with gametocytes at the time of PQ administration (n 554) and for
safety in glucose-6-phosphate dehydrogenase (G6PD)-deﬁcient individuals treated
with PQ (n 110). Individuals with a genetically inferred CYP2D6 poor/intermediate
metabolizer status had a higher gametocyte prevalence on day 7 or 10 after PQ
than those with an extensive/ultrarapid CYP2D6 metabolizer status (odds ratio
[OR]  1.79 [95% conﬁdence interval {CI}, 1.10, 2.90]; P 0.018). The mean minimum
hemoglobin concentrations during follow-up for G6PD-deﬁcient individuals were
11.8 g/dl for CYP2D6 extensive/ultrarapid metabolizers and 12.1 g/dl for CYP2D6
poor/intermediate metabolizers (P 0. 803). CYP2D6 genetically inferred metabolizer
status was also not associated with anemia following PQ treatment (P 0.331). We
conclude that CYP2D6 poor/intermediate metabolizer status may be associated
with prolonged gametocyte carriage after treatment with single-low-dose PQ but
not with treatment safety.
KEYWORDS cytochrome P450, drug metabolism, elimination, gametocyte, genetic
polymorphisms, malaria, metabolite, primaquine, safety, transmission
With recent successes in malaria control and the move toward Plasmodium falcip-arum elimination, there is an increasing interest in transmission-reducing strat-
egies. One of the tools available is single-low-dose (0.25 mg/kg of body weight)
primaquine (PQ) added to artemisinin combination therapy (ACT). PQ is a drug in the
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class of 8-aminoquinolines that has been on the market for more than 70 years. In
recent years, the addition of PQ to ACTs has received considerable interest because of
its ability to rapidly clear mature P. falciparum gametocytes and reduce the infectious
period compared to ACT alone (1–6).
Cytochrome P450 2D6 (CYP2D6) is a human enzyme involved in the metabolization
of 20 to 25% of all prescribed medicines (7–10). Hundreds of different CYP2D6 alleles
have been discovered, some of which inﬂuence the activity of the produced enzyme
(11). Bennett and colleagues ﬁrst associated genetic CYP2D6 variation with relapses of
Plasmodium vivax malaria after PQ treatment (12). More recently, genetic CYP2D6
variation was found to be strongly associated with an increased risk of relapses among
Indonesian patients with clinical P. vivax malaria (7). There is also evidence in mice that
enzymes in the CYP2D family produce the active metabolite of PQ against Plasmodium
berghei liver stages (13), but metabolic activation of PQ may not be necessary to
eradicate blood stages (14).
The implications of genetic CYP2D6 variation for the use of PQ in P. falciparum
infections have never been explored. One of the factors that has hindered the wide-
spread adoption of PQ for P. falciparum transmission reduction is its safety proﬁle,
notably in individuals with genetic deﬁciencies in glucose-6-phosphate dehydrogenase
(G6PD) production (12, 15–17). G6PD is an enzyme involved in the pentose phosphate
pathway in human red blood cells (18), and G6PD deﬁciency (G6PDd) is associated with
hemolysis following treatment with PQ. Despite safety concerns related to the hemo-
lytic activity of PQ in individuals with G6PDd, a single low dose of PQ is considered safe
in individuals with the most common African G6PDd variant (G6PDd A variant) (19–21).
Since genetic variation in CYP2D6 inﬂuences the pharmacokinetics of single-low-dose
PQ in humans (22), this variation may have implications for PQ efﬁcacy or safety at
doses targeting P. falciparum gametocytes.
Here, we determine the impact of genetically inferred CYP2D6 metabolizer status on
the gametocytocidal and hemolytic effect of single-dose PQ in 8 clinical trials con-
ducted across Africa.
RESULTS
CYP2D6 genotyping with the OpenArray technology used here requires high-quality
DNA, ideally 50 ng/l, a condition that was not always met. CYP2D6 genotyping was
thus successful in 72% (774/1,076) of all samples; success varied considerably between
sample types, with good success rates for saliva samples (98%) and large-volume
blood samples (0.5 ml blood) (success rate of 87%) but low success rates for
different sample types (1 to 68%) (Table 1; see also Data Set S1 in the supplemental
material). As a result of differences in sample collection methods between sites,
genotyping was successful for 58% of samples from Uganda and Balonghin, Burkina
Faso, but for80% of samples for other sites (Table 1 and Data Set S1). Inference of the
CYP2D6 activity score (AS) from genotypes was successful in 68% (731/1,076) of
samples and is presented for the different sites in Fig. 1. The CYP2D6 AS inference
allowed classiﬁcation of sample donors as poor metabolizer (PM) (activity score of 0),
intermediate metabolizer (IM) (activity score of 0.5 to 1.0), extensive metabolizer (EM)
(activity score of 1.5 to 2.0), or ultrarapid metabolizer (UM) (activity score of 2.0). For
other samples, a range of ASs could be inferred that allowed classiﬁcation into EM/UM
classes (AS 1.5; n 137) (Data Set S2). CYP2D6 PM status was inferred for a minority
of individuals (2.6%; 19/731); CYP2D6 IM status was inferred for 38.2% of individuals
(279/731).
A total of 544 participants from 5 studies who had gametocytes by molecular
methods on the day of initiation of treatment, completed treatment, and had complete
outcome measures were included in the efﬁcacy analysis. The prevalence of CYP2D6
PM/IM status among these individuals was 31.4% (171/544) overall and ranged from
26% to 41% by study. Compared to ACT alone, PQ was effective in reducing gameto-
cyte prevalence on day 7 or 10 in both CYP2D6 EM/UM (odds ratio [OR]  0.20 [95%
conﬁdence interval {CI}, 0.11, 0.36]; P 0.001) and CYP2D6 PM/IM (OR  0.15 [95% CI,
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0.05, 0.44]; P 0.001) individuals. Individuals with CYP2D6 PM/IM status had a higher
gametocyte prevalence at day 7 or 10 after PQ treatment than those with CYP2D6
EM/UM status (Table 2), after adjusting for PQ dose, country, and baseline gametocyte
density (OR  1.79 [95% CI, 1.10 to 2.90]; P 0.018).
For the safety analysis, PQ was administered to 110 G6PDd individuals in 7 different
FIG 1 Genotypically inferred CYP2D6 AS for six African populations. Only samples for which an exact AS
was inferred are included (n/N, where n is the number of individuals for whom an AS was determined
and N is the number of samples for which genotyping was attempted). It was not possible to infer ASs
for all individuals with a determined genotype due to not knowing which haplotype is duplicated (see
Data Set S1 in the supplemental material). In some cases, it was possible to determine an AS range (Data
Set S2) but not an exact AS. For Mali and the Gambia, results from efﬁcacy and safety studies were
combined; in Burkina Faso (BF), the efﬁcacy and safety studies were carried out in two distinct
populations in different areas, and therefore, the AS results are presented separately for the Balonghin
and Banfora populations.
TABLE 2 Effect of CYP2D6 metabolizer status and covariates on gametocyte prevalence at day 7 or 10 among individuals receiving
primaquine
Covariate
No. of individuals with
gametocytes on day 7 or
10/total no. of individuals (%) OR (95% CI) Adjusted ORa (95% CI)
CYP2D6 status P  0.028 P  0.018
EM/UM 80/289 (28) 1 1
PM/IM 51/133 (38) 1.62 (1.05–2.50) 1.79 (1.10–2.90)
Baseline gametocyte density/ml 1.002 (1.000–1.003) (P  0.005) 1.002 (1.001–1.003) (P  0.004)
Baseline asexual parasite density/ml 0.998 (0.994, 1.002) (P  0.380) 0.994 (0.982, 0.999) (P  0.025)
PQ dose (mg/kg) P  0.001 P  0.001
0.25 89/228 (39) 1 1
0.5 30/153 (20) 0.38 (0.24–0.62) 0.32 (0.18–0.56)
0.75 12/41 (29) 0.65 (0.31–1.33) 0.34 (0.14–0.82)
Country P  0.001 P  0.001
Burkina Faso 26/166 (16) 1 1
Kenya 20/50 (40) 3.59 (1.78–7.26) 2.24 (1.07–4.74)
Mali 21/43 (49) 5.14 (2.48–10.66) 6.05 (2.76–13.25)
Gambia 24/61 (39) 3.49 (1.80–6.78) 3.27 (1.62–6.59)
Uganda 40/102 (39) 3.47 (1.95–6.19) 4.19 (2.03–8.64)
aAdjusted for all other factors in the table.
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studies. Among these PQ-treated G6PDd individuals, 56% (62/110) were EM/UM and
possibly at risk of more severe hemolysis due to increased availability of the active
metabolite(s) of PQ. The pretreatment mean hemoglobin (Hb) concentrations were 13.3
g/dl in the CYP2D6 EM/UM G6PDd individuals and 13.4 g/dl in the CYP2D6 PM/IM
G6PDd individuals (P 0.803). The mean minimum Hb concentrations during 10 to
28 days of follow-up were 11.8 g/dl for CYP2D6 EM/UM G6PDd individuals and 12.1 g/dl
for CYP2D6 PM/IM G6PDd individuals. This difference, adjusted for baseline Hb con-
centration, country, and primaquine dose, was 0.05 g/dl (95% CI, 0.34, 0.44)
(P 0.803) and not statistically signiﬁcant. One hundred individuals had Hb measure-
ment on day 7 posttreatment: the mean Hb concentrations on day 7 were 12.5 g/dl for
CYP2D6 EM/UM G6PDd individuals and 12.8 g/dl for CYP2D6 PM/IM G6PDd individuals
(adjusted difference, 0.25 g/dl [95% CI, 0.24, 0.74]; P 0.314). Twenty-four percent
(15/62) of CYP2D6 EM/UM G6PDd individuals experienced moderate anemia, compared
to 23% (11/48) of CYP2D6 PM/IM G6PDd individuals (adjusted odds ratio, 2.11 [95% CI,
0.46, 9.72]; P 0.334). Only one G6PDd individual from Burkina Faso had severe anemia
after PQ treatment (Hb concentration of 7 g/dl at day 10); this individual was CYP2D6
EM/UM, had a baseline Hb concentration of 12.5 g/dl, and recovered completely by day
14 (Hb concentration of 11.9 g/dl).
Although the CYP2D6 genotyping success was low for some sample sets, genotyp-
ing success was not associated with persisting gametocytes on day 7 or 10 (OR  0.95
[95% CI, 0.65 to 1.38]; P 0.771) or Hb (difference of 0.83 [95% CI, 1.91, 0.25];
P 0.129) in models adjusted for country, PQ dose, and baseline gametocyte density.
We thus found no evidence for selection bias in our efﬁcacy and safety outcome
assessments due to variation in CYP2D6 genotyping success.
DISCUSSION
In the present study, we utilized samples from clinical trials across Africa to explore
the effect of genetically inferred CYP2D6 metabolizer status on PQ efﬁcacy and safety.
Compared to ACT alone, the addition of single-dose PQ resulted in a marked reduction
in gametocyte carriage across populations with different CYP2D6 metabolizer statuses.
Nevertheless, CYP2D6 PM/IM individuals were more likely to have persisting gameto-
cytes until day 7 or 10 following initiation of treatment with ACT-PQ.
While the transmission-blocking effect of PQ may precede the gametocyte-clearing
effect and gametocytes persisting after PQ may not result in onward transmission to
mosquitoes (1, 6, 23), the results of the present study suggest that the efﬁcacy of
low-dose PQ may be affected by CYP2D6 metabolizer status. We previously demon-
strated that PQ pharmacokinetics are inﬂuenced by genetically inferred CYP2D6 me-
tabolizer status (22), suggesting that lower concentrations of the PQ active metabolites
may occur in CYP2D6 PM/IM individuals. While CYP2D6 metabolizer status and con-
centrations of active PQ metabolites have direct implications for P. vivax-infected
patients by affecting cure rates (12), the effect on P. falciparum-infected patients is
indirect, potentially increasing the number of secondary cases arising from a PQ-treated
gametocyte carrier.
We observed no effect of CYP2D6 metabolizer status on Hb concentrations after PQ
treatment of G6PDd individuals. We hypothesized that G6PDd individuals with CYP2D6
PM/IM status would be relatively protected from hemolysis, but this was not observed.
While we combined data from safety studies to maximize the number of observations
in G6PDd individuals, it is possible that our study population size was insufﬁcient to
detect subtle effects on hemolysis. Interstudy variation may also have obscured effects
of CYP2D6 status, although study site was incorporated into our multivariate regression
models.
There are several limitations to this study. We worked with available samples from
several clinical trials, not speciﬁcally collecting material for extensive human genotyp-
ing. The variable quality and quantity of samples affected our genotyping success rate
but are unlikely to have affected the validity of our comparisons between populations
with successful genotyping results. Similarly, the present study did not allow us to
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detect possible differences in effects between ACTs. CYP2D6 activity and PQ metabo-
lism may be inﬂuenced differently by dihydroartemisinin-piperaquine (DP) (24) and
artemether-lumefantrine (AL) (25). While we combined ﬁndings from trials with differ-
ent ACTs, this is unlikely to have affected the validity of our ﬁndings, and we adjusted
for study effects. Another limitation is that we inferred CYP2D6 metabolizer status from
the CYP2D6 genotype. There has been a series of publications describing situations
where the commercially available TaqMan assays, also used here in the OpenArray
format, have not worked as expected and have been redesigned (26–29). Most signif-
icantly, one assay variant detecting CYP single nucleotide polymorphisms (SNPs) (*15
allele; C_32407245_40) suffers from interference from the sequence of the pseudogene
CYP2D7 to the extent that these results were not included in the analysis (27). Some
additional assays have been replaced with new and improved ones during the
course of this study (*7 assay [C_32388575_30 with C_32388575_A0], *8 assay
[C_30634117C_20 with C_30634117C_K0], and *14 assay [C_30634117D_30 with
C_30634117D_M0]) (30). In addition, a copy number variation (CNV) assay targeting
intron 2 (Hs04083572_cn) may not always give the correct result due to intronic
polymorphisms, and CNV assays in general work only with high sample quality (and not
after product preampliﬁcation). These challenges in genetic analysis underline the
complexity of the locus and the need for more sequencing of CYP2D6. Especially in
African populations for which pharmacogenetic data are lacking, additional data are
needed (31). Such future studies may purposefully collect select samples for human
genotyping. In our studies, 0.5 to 1 ml blood collected in ethylenediaminetetraacetic
acid (EDTA)-coated tubes or Oragene saliva samples resulted in high genotyping
success rates (Table 1). Another option is to perform CYP2D6 phenotyping experiments,
where a probe substrate to assess CYP2D6 activity is used. Although substrate speci-
ﬁcity may complicate extrapolation of data from such assays to PQ metabolism, an
unquestionable advantage of phenotyping is that it would take into consideration
environmental factors inﬂuencing CYP2D6 activity. These include, but are not limited
to, comorbidities, concomitant medication, and food intake (32, 33).
Despite limitations, including the modest number of observations from individuals
with the genetically inferred CYP2D6 PM phenotype, we present evidence that CYP2D6
PM/IM status is associated with prolonged gametocyte carriage after treatment. It is
currently unclear whether this has implications for the transmission-blocking effects of
PQ at the population level in malaria elimination settings. A clinically meaningful effect
of genetically inferred CYP2D6 metabolizer status on PQ-induced hemolysis in G6PDd
individuals is unlikely.
MATERIALS AND METHODS
Study samples. Samples from 8 published clinical trials were used for separate analyses on the
impact of genetically inferred CYP2D6 metabolizer status on PQ safety and efﬁcacy. For analyses of the
impact of CYP2D6 inferred metabolizer status on PQ efﬁcacy, we included samples from 5 PQ efﬁcacy
studies. Gametocyte detection was performed following treatment with a single dose of 0.1 to
0.75 mg/kg PQ in combination with either artemether-lumefantrine (AL) (Coartem as a standard
6-dose regimen over 3 days; Novartis Pharma, Switzerland) in Burkina Faso (3) and Uganda (2) or
dihydroartemisinin-piperaquine (DP) (Eurartesim as a standard 3-day regimen; Sigma-Tau, Italy) in
Mali (1), the Gambia (4), and Kenya (5). Analyses on the impact of CYP2D6 inferred metabolizer status
on hemolysis were restricted to G6PD-deﬁcient (G6PDd) individuals; we included two additional studies
that speciﬁcally assessed PQ safety in G6PD-deﬁcient individuals in Mali (20) and the Gambia (19), using
0.25 to 0.5 mg/kg PQ in combination with DP. In all studies, hemoglobin (Hb) concentrations in grams
per deciliter were measured by a self-calibrating HemoCue photometer (Ängelholm, Sweden). Study
details are summarized in Table 1.
Extraction of nucleic acids. An automated MagNA Pure LC 2.0 instrument (Roche, Switzerland) was
used for extraction of total nucleic acid (NA) or DNA. For the samples from Uganda as well as the parasitology
samples from Mali, a MagNA Pure LC high-performance total nucleic acid isolation kit was used. For samples
from Burkina Faso, Kenya, and the ﬁrst season of the trial in the Gambia (both full blood in EDTA and saliva
samples), MagNA Pure LV DNA isolation kits were used. The saliva samples collected after the second season
of the trial in the Gambia were extracted using a Maxwell 16 instrument (Promega, USA) and Maxwell 16 DNA
puriﬁcation kits. Concentration measurements were done using a NanoDrop device (Thermo Fisher, USA)
(only DNA from full blood in EDTA) and a Qubit ﬂuorometer (Thermo Fisher, USA) with the Qubit HS
(high-sensitivity) kit, which is speciﬁc for double-stranded DNA (dsDNA).
Pett et al. Antimicrobial Agents and Chemotherapy
October 2019 Volume 63 Issue 10 e00538-19 aac.asm.org 6
 o
n
 N
ovem
ber 1, 2019 at TERKKO
 NATIO
NAL LIBRARY O
F HEALTH SCIENCES
http://aac.asm
.org/
D
ow
nloaded from
 
Gametocyte detection. Quantitative nucleic acid sequence-based ampliﬁcation (QT-NASBA) was
performed as described previously by Schneider et al. (34), and quantitative reverse transcription-
quantitative PCR (qRT-PCR) was performed as described previously by Wampﬂer et al. (35). Brieﬂy, total
NA was used for ampliﬁcation of the P. falciparum mature gametocyte marker Pfs25 mRNA for the
estimation of mature gametocyte density in samples from the clinical trials. Gametocyte densities were
assigned based on plate-speciﬁc gametocyte dilution series, which were diluted in whole blood before
extraction of total NA, as with the samples from the clinical trials. For samples from trial participants,
estimated gametocyte densities below 0.02 gametocytes per l were considered to be negative.
Ethical considerations. Informed consent was obtained from all study participants. The studies
received approval from the Ethics Committee of the Faculty of Medicine, Pharmacy, and Dentistry,
University of Science, Techniques and Technologies of Bamako, and the Committee on Human Research
at the University of California, San Francisco (studies in Mali); the Comité d’Ethique pour la Recherche en
Santé, Ministère de la Santé du Burkina Faso, and the Comité Technique d’Examen des Demandes
d’Autorisation d’Essais Cliniques, Ministère de la Santé du Burkina Faso (studies in Burkina Faso); the
Gambia Government/MRC Joint Ethics Committee (studies in the Gambia); the Makerere University
School of Medicine research ethics committee and the Uganda National Council of Science and
Technology (study in Uganda); the Kenya Medical Research Institute Ethics Review Committee (study in
Kenya); and the Interventions Research Ethics Committee of the London School of Hygiene and Tropical
Medicine (all studies).
CYP2D6 metabolizer status. Samples with sufﬁcient quantities of DNA (50 ng/l without or
2.5 ng/l with the manufacturer-provided preampliﬁcation kit) were genotyped for CYP2D6 *2, *3, *4, *6,
*7, *8, *9, *10, *11, *15, *17, *18, *19, *20, *29, *40, and *41 alleles using OpenArray technology on a
QuantStudio 12K Flex RT-PCR system (Life Technologies, Carlsbad, CA, USA). The CYP2D6 copy number
was determined with at least one TaqMan copy number assay targeting intron 2 (Hs04083572_cn), intron
6 (Hs04502394_cn), and/or exon 9 (Hs00010001_cn), depending on the available sample quality and
volume. CYP2D6 metabolizer status was inferred from the genotypes using the activity score (AS) (36).
An AS of 0.0 indicates a poor metabolizer (PM), an AS of 0.5 to 1.0 indicates an intermediate metabolizer
(IM), an AS of 1.5 to 2.0 indicates an extensive metabolizer (EM), and an AS of2.0 indicates an ultrarapid
metabolizer (UM) (37). For the analyses, we compared PM/IM versus EM/UM.
Statistical analysis. As a single measure of PQ efﬁcacy, we used the presence of gametocytes on
either day 7 or day 10. The effect on Hb was quantiﬁed in two ways: the day 7 Hb concentration (from
studies with day 7 measurements) and the minimum observed Hb concentration (from all studies; up to
day 28 after initiation of treatment). Because different trials used different PQ doses, the PQ dose was
categorized as no PQ (control arms), 0.25 mg/kg PQ (0.10 to 0.25 mg/kg), 0.5 mg/kg PQ (0.4 to 0.5 mg/kg),
or 0.75 mg/kg PQ. Anemia was deﬁned based on criteria of the World Health Organization (38): moderate
anemia was deﬁned as an Hb concentration of 11 g/dl for adults or 10g/dl for children 5 years of
age, and severe anemia was deﬁned as an Hb concentration of 8 g/dl for adults or 7g/dl for children
5 years of age. Logistic and linear regression models were used to analyze the effect of CYP2D6 status
on gametocyte prevalence, anemia, and Hb concentration. Models controlled for PQ dose, study,
baseline gametocyte and asexual parasite densities (in efﬁcacy analyses), and baseline Hb concentration
(in safety analyses).
SUPPLEMENTAL MATERIAL
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